Skip to content

Personalized management of high blood pressure in Anhui, China

Personalized Hypertension Management (PHMA) based on serial assessment and telemedicine in Anhui, China

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN10999269
Enrollment
3420
Registered
2020-07-17
Start date
2020-08-01
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension Circulatory System Hypertension

Interventions

The study adopts a cluster randomized controlled trial (RCT) design involving a total of 60 site communities with 12 in the control arm and 48 in the intervention arm. The control arm maintains existi
while the intervention arms, personalized hypertension management (PHMA). Project evaluation applies to all arms using the same data collection methods and by the same field data collectors. And detai

Sponsors

National Natural Science Foundation of China
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged =18 years 2. Living in the selected villages for =6 months/year 3. Diagnosed with hypertension

Exclusion criteria

Exclusion criteria: Previous diagnosis of mental illness, serious illness, or disability

Design outcomes

Primary

MeasureTime frame
Systolic BP/Diastolic BP measured using mercury sphygmomanometer at baseline and every 12 months after baseline for 5 years

Secondary

MeasureTime frame
1. Quality of life 2. Occurrence of hypertension-related complications (such as cerebral hemorrhage, coronary heart disease, myocardial infarction, cerebral infarction) 3. Healthcare utilization 4. Scores of objective behaviors All secondary outcome measures will be measured using structured questionnaires at baseline and every 12 months after baseline for 5 years

Countries

China

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 15, 2026